The investor-backed provider community may be feeling pressure and facing scrutiny from various angles in 2024, as federal and state agencies implement complex pre-closing review processes for healthcare transactions from an antitrust and oversight perspective. In addition, federal and state agencies continue to focus their efforts on combating fraud and abuse. On the economic side, high interest rates impact valuations and execution risk. As these factors affect deal flow and company margins, healthcare portfolio companies may want to focus on internal platform clean-up actions and implement compliance measures to best position themselves in this environment.
Read the full article: Ten Action Items for Healthcare Portfolio Companies in 2024 //
Source: https://www.jdsupra.com/legalnews/ten-action-items-for-healthcare-1886524/